Oxford BioMedica
Discover Realise


OXB-202 is a lentiviral vector based treatment designed to prevent corneal graft rejection.

Cornea grafts are one of the most successful tissue transplants but, over time, a significant number of grafts are rejected due to corneal neovascularisation. OXB-202 is designed to genetically modify human donor corneas to secrete two anti-angiogenesis proteins, endostatin and angiostatin, to inhibit neovascularisation and prevent rejection. It is anticipated that the clinical trial application for the Phase I/II clinical study will be submitted in 2017, and patients could commence treatment in 2017, again, subject to successfully out-licensing or spinning out the product. The first site for the clinical study is likely to be at Moorfields Eye Hospital in London although further sites, potentially in the US, may be opened once the study is underway.